Company intelligence / Profile preview

QED Medical

Palo Alto, California, United Statesqed-medical.com ↗

Ownership: Private
Development stage: Commercial

Overview

QED Therapeutics develops targeted therapies for rare genetic skeletal disorders. Its lead program, infigratinib, an oral FGFR inhibitor, has received FDA Breakthrough Therapy Designation for achondroplasia and is being evaluated in ongoing clinical studies. The company focuses on addressing the underlying genetic causes of conditions like achondroplasia and hypochondroplasia by targeting FGFR3 overactivity. Infigratinib remains investigational and not yet approved by regulatory authorities.

Therapeutic areas: Rare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Parent company relationship with BridgeBio Pharma

Beyond the preview

Go deeper on QED Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QED Medical.

Explore the full profile